Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 1 35 versus LUPANETA PACK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 1 35 versus LUPANETA PACK.
CYCLAFEM 1/35 vs LUPANETA PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH, LH) secretion via estrogen and progestin negative feedback, inhibiting ovulation. Progestin alters cervical mucus (sperm penetration) and endometrial receptivity.
Leuprolide is a synthetic GnRH analog that desensitizes pituitary GnRH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).
One tablet orally once daily. Each tablet contains 1 mg norethindrone and 0.035 mg ethinyl estradiol. Administer daily for 21 days followed by 7 days of placebo or no tablet.
Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.
None Documented
None Documented
Half-life of norethindrone is 5-14 hours; ethinyl estradiol is 10-20 hours. Steady state reached after 5-7 days.
Terminal elimination half-life is 6-12 hours (mean 8 hours). Clinical context: supports twice-daily dosing; prolonged in severe renal impairment (CrCl <30 mL/min).
Renal 40-60% as glucuronide and sulfate conjugates, biliary/fecal 20-40%.
Renal excretion accounts for approximately 50% of the total clearance as unchanged drug, with the remainder undergoing hepatic metabolism followed by biliary/fecal elimination (approx. 30% fecal, 20% biliary).
Category C
Category C
Oral Contraceptive
Oral Contraceptive